Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
RMTI's Cash to Debt is ranked higher than
98% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. RMTI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RMTI' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 27.81 Max: No Debt
Current: No Debt
Equity to Asset 0.71
RMTI's Equity to Asset is ranked higher than
64% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. RMTI: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
RMTI' s Equity to Asset Range Over the Past 10 Years
Min: -0.59  Med: 0.63 Max: 0.92
Current: 0.71
-0.59
0.92
F-Score: 6
Z-Score: 5.51
M-Score: -3.21
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -25.26
RMTI's Operating margin (%) is ranked lower than
84% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.82 vs. RMTI: -25.26 )
Ranked among companies with meaningful Operating margin (%) only.
RMTI' s Operating margin (%) Range Over the Past 10 Years
Min: -108.87  Med: -15.92 Max: 0.49
Current: -25.26
-108.87
0.49
Net-margin (%) -27.01
RMTI's Net-margin (%) is ranked lower than
85% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.45 vs. RMTI: -27.01 )
Ranked among companies with meaningful Net-margin (%) only.
RMTI' s Net-margin (%) Range Over the Past 10 Years
Min: -108.39  Med: -15.60 Max: 0.28
Current: -27.01
-108.39
0.28
ROE (%) -28.75
RMTI's ROE (%) is ranked lower than
84% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. RMTI: -28.75 )
Ranked among companies with meaningful ROE (%) only.
RMTI' s ROE (%) Range Over the Past 10 Years
Min: -1304.41  Med: -52.81 Max: 2.12
Current: -28.75
-1304.41
2.12
ROA (%) -18.72
RMTI's ROA (%) is ranked lower than
83% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. RMTI: -18.72 )
Ranked among companies with meaningful ROA (%) only.
RMTI' s ROA (%) Range Over the Past 10 Years
Min: -220.66  Med: -34.71 Max: 0.91
Current: -18.72
-220.66
0.91
ROC (Joel Greenblatt) (%) -371.49
RMTI's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.76 vs. RMTI: -371.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RMTI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2678.13  Med: -126.44 Max: 6.35
Current: -371.49
-2678.13
6.35
Revenue Growth (3Y)(%) -21.90
RMTI's Revenue Growth (3Y)(%) is ranked lower than
90% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. RMTI: -21.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RMTI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -23  Med: 1.70 Max: 36.8
Current: -21.9
-23
36.8
EBITDA Growth (3Y)(%) -30.10
RMTI's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. RMTI: -30.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RMTI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -36.2  Med: -15.70 Max: 159.6
Current: -30.1
-36.2
159.6
EPS Growth (3Y)(%) -24.70
RMTI's EPS Growth (3Y)(%) is ranked lower than
82% of the 487 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. RMTI: -24.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RMTI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -18.30 Max: 111.4
Current: -24.7
0
111.4
» RMTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RMTI Guru Trades in

Q1 2015

RMTI Guru Trades in Q1 2015

Paul Tudor Jones 25,170 sh (New)
» More
Q2 2015

RMTI Guru Trades in Q2 2015

Paul Tudor Jones 26,035 sh (+3.44%)
» More
Q3 2015

RMTI Guru Trades in Q3 2015

Paul Tudor Jones 49,916 sh (+91.73%)
» More
» Details

Insider Trades

Latest Guru Trades with RMTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 17.79
RMTI's Forward P/E is ranked higher than
58% of the 236 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.62 vs. RMTI: 17.79 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 4.87
RMTI's P/B is ranked lower than
73% of the 706 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. RMTI: 4.87 )
Ranked among companies with meaningful P/B only.
RMTI' s P/B Range Over the Past 10 Years
Min: 1.73  Med: 7.78 Max: 1425
Current: 4.87
1.73
1425
P/S 5.42
RMTI's P/S is ranked lower than
73% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.72 vs. RMTI: 5.42 )
Ranked among companies with meaningful P/S only.
RMTI' s P/S Range Over the Past 10 Years
Min: 0.47  Med: 2.27 Max: 15.01
Current: 5.42
0.47
15.01
PFCF 62.30
RMTI's PFCF is ranked lower than
69% of the 248 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. RMTI: 62.30 )
Ranked among companies with meaningful PFCF only.
RMTI' s PFCF Range Over the Past 10 Years
Min: 36.5  Med: 102.20 Max: 372.33
Current: 62.3
36.5
372.33
POCF 56.64
RMTI's POCF is ranked lower than
72% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.79 vs. RMTI: 56.64 )
Ranked among companies with meaningful POCF only.
RMTI' s POCF Range Over the Past 10 Years
Min: 25  Med: 60.36 Max: 186.17
Current: 56.64
25
186.17
Current Ratio 10.37
RMTI's Current Ratio is ranked higher than
92% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.27 vs. RMTI: 10.37 )
Ranked among companies with meaningful Current Ratio only.
RMTI' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.89 Max: 12.58
Current: 10.37
0.49
12.58
Quick Ratio 9.50
RMTI's Quick Ratio is ranked higher than
91% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. RMTI: 9.50 )
Ranked among companies with meaningful Quick Ratio only.
RMTI' s Quick Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.53 Max: 11.68
Current: 9.5
0.35
11.68
Days Inventory 40.80
RMTI's Days Inventory is ranked higher than
88% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.46 vs. RMTI: 40.80 )
Ranked among companies with meaningful Days Inventory only.
RMTI' s Days Inventory Range Over the Past 10 Years
Min: 21.24  Med: 23.36 Max: 33.28
Current: 40.8
21.24
33.28
Days Sales Outstanding 38.66
RMTI's Days Sales Outstanding is ranked higher than
82% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.01 vs. RMTI: 38.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
RMTI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.3  Med: 32.18 Max: 44.28
Current: 38.66
23.3
44.28
Days Payable 41.26
RMTI's Days Payable is ranked lower than
77% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.59 vs. RMTI: 41.26 )
Ranked among companies with meaningful Days Payable only.
RMTI' s Days Payable Range Over the Past 10 Years
Min: 26.41  Med: 39.97 Max: 125.48
Current: 41.26
26.41
125.48

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.70
RMTI's Price/Net Cash is ranked higher than
61% of the 201 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.02 vs. RMTI: 6.70 )
Ranked among companies with meaningful Price/Net Cash only.
RMTI' s Price/Net Cash Range Over the Past 10 Years
Min: 4.11  Med: 15.47 Max: 394
Current: 6.7
4.11
394
Price/Net Current Asset Value 5.11
RMTI's Price/Net Current Asset Value is ranked higher than
63% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. RMTI: 5.11 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RMTI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.27  Med: 11.12 Max: 315
Current: 5.11
3.27
315
Price/Tangible Book 4.94
RMTI's Price/Tangible Book is ranked lower than
65% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.51 vs. RMTI: 4.94 )
Ranked among companies with meaningful Price/Tangible Book only.
RMTI' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.67  Med: 8.23 Max: 95
Current: 4.94
2.67
95
Price/Median PS Value 2.38
RMTI's Price/Median PS Value is ranked lower than
83% of the 612 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. RMTI: 2.38 )
Ranked among companies with meaningful Price/Median PS Value only.
RMTI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.18  Med: 0.88 Max: 5.93
Current: 2.38
0.18
5.93
Earnings Yield (Greenblatt) (%) -5.50
RMTI's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. RMTI: -5.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RMTI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.8  Med: 1.20 Max: 1.4
Current: -5.5
0.8
1.4

More Statistics

Revenue(Mil) $56
EPS $ -0.31
Beta3.26
Short Percentage of Float20.83%
52-Week Range $5.90 - 18.90
Shares Outstanding(Mil)51.08

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 56 120 86 93
EPS($) -0.19 0.85 0.35 0.48
EPS without NRI($) -0.19 0.85 0.35 0.48

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:RWM.Germany,
Rockwell Medical Inc was incorporated in the state of Michigan in 1996. The Company is a fully-integrated biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a full line of ancillary products, to customers in the U.S. and abroad. Dialysate concentrates account for over 93% of its revenue and consist of two products known in the industry as acid and bicarbonate and are packaged as liquid or powder. All of its products are manufactured according to Association for the Advancement of Medical Instrumentation and current good manufacturing practices guidelines. Its concentrate products are used in conjunction and are diluted with clean water on-site at the clinic in the dialysis machine, creating dialysate, which works to clean the patient's blood. Its CitraPure concentrate is 100% acetate-free, in contrast to the acetate-based products used for many years. Acetate promotes inflammation so its removal is beneficial to the patient. Dry powder acid concentrate for use with its Dry Acid Mixing System, containing acetic acid, sodium chloride, dextrose and electrolyte additives such as magnesium, potassium, and calcium. It supplies dry acid in 25 gallon cases. Its Dry Acid Concentrate Mixing System is designed for its CitraPure and Dri-Sate Dry Acid product and allows a clinic to mix its acid concentrate on-site. The clinic technician, using a specially designed mixer, adds pre-measured packets of the necessary ingredients to purified water. RenalPure bicarbonate sold in powder form is used mainly in chronic settings. Each clinic mixes bicarbonate on-site as required. SteriLyte bicarbonate is sold in liquid form and is used in acute care settings. It offers ancillary products including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts and other supplies used by hemodialysis providers. Its largest competitor is U.S. based Fresenius Medical Care NA, which is mainly in the business of operating dialysis clinics, as well as manufacturing and marketing dialysis devices, drugs and supplies. The testing, manufacture and sale of its hemodialysis concentrates and the ancillary products it distribute are subject to regulation by numerous governmental authorities, mainly the FDA and corresponding state and foreign agencies.
» More Articles for RMTI

Headlines

Articles On GuruFocus.com
Brean Capital’s Top Ideas for 2015 Dec 24 2014 
Rockwell Medical Technologies Inc. (RMTI) Chairman, President and CEO, 10% Owner Robert L Chioini se Jan 03 2011 
Rockwell Medical Technologies Inc. (RMTI) Vice President, CFO Thomas E Klema sells 15,000 Shares Jan 03 2011 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Nov 04 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Aug 05 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) May 07 2010 
Rockwell Medical Technologies Inc. (RMTI) Chairman, President and CEO, 10% Owner Robert L Chioini se Jan 04 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Nov 06 2009 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Aug 10 2009 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
Rockwell Medical Announces Two Triferic® Poster Presentations Accepted for Presentation at National... Jan 19 2016
Rockwell Medical Announces Two Triferic® Poster Presentations Accepted for Presentation at National... Jan 19 2016
Where Opportunity is Found - New Research on GFI Group, Rockwell Medical, Planet Fitness and... Dec 28 2015
Rockwell Medical, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 18 2015
ROCKWELL MEDICAL, INC. Financials Dec 08 2015
Rockwell Medical, Inc. – Value Analysis (NASDAQ:RMTI) : December 7, 2015 Dec 07 2015
Rockwell Medical, Inc. breached its 50 day moving average in a Bullish Manner : December 7, 2015 Dec 07 2015
Rockwell Medical to Present at Oppenheimer 26th Annual Healthcare Conference Dec 01 2015
Rockwell Medical to Present at Oppenheimer 26th Annual Healthcare Conference Dec 01 2015
Rockwell Medical's Triferic Receives Permanent J-Code for Renal Drug Reimbursement Nov 30 2015
Rockwell Medical's Triferic Receives Permanent J-Code for Renal Drug Reimbursement Nov 30 2015
What Do Hedge Funds Think Of DXP Enterprises Inc (DXPE)? Nov 28 2015
Rockwell Medical Inc (RMTI)Hedge Funds Are Snapping Up Nov 26 2015
Rockwell Medical to Present at Stifel 2015 Healthcare Conference Nov 12 2015
Rockwell Medical to Present at Stifel 2015 Healthcare Conference Nov 12 2015
Rockwell Medical trade sees floor Nov 11 2015
Rockwell Medical reports 3Q loss Nov 09 2015
Rockwell Medical reports 3Q loss Nov 09 2015
Rockwell Medical Inc Earnings Call scheduled for 4:30 pm ET today Nov 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK